{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:26:53Z","timestamp":1788964013348,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["ICI20\/00033"],"award-info":[{"award-number":["ICI20\/00033"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:45:01Z","timestamp":1783604701000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility and Interim Safety and Efficacy Analysis of a Fast Automated Production of Prophylactic Cytomegalovirus-Specific Cytotoxic T Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9529-769X","authenticated-orcid":false,"given":"Ma Ar\u00e1nzazu","family":"Berm\u00fadez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8718-9920","authenticated-orcid":false,"given":"Oscar M.","family":"Pello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6247-1516","authenticated-orcid":false,"given":"Miriam","family":"S\u00e1nchez-Escamilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Vallejo-D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-4481","authenticated-orcid":false,"given":"Marta","family":"Fern\u00e1ndez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Lav\u00edn-Alconero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Colorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Rom\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gala A.","family":"M\u00e9ndez-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-5893","authenticated-orcid":false,"given":"Sara","family":"Fern\u00e1ndez-Luis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Insunza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9265-7310","authenticated-orcid":false,"given":"Laura","family":"Alvarez-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"LLorente-Mecieces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Maiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7076-7739","authenticated-orcid":false,"given":"Ferm\u00edn","family":"S\u00e1nchez-Guijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-0085","authenticated-orcid":false,"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2026.07.001_bib0001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after hematopoietic cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.001_bib0003","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/338624","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection","volume":"185","author":"Nichols","year":"2002","journal-title":"J Infect Dis"},{"issue":"18","key":"10.1016\/j.jtct.2026.07.001_bib0004","first-page":"1503","article-title":"How I prevent cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation","volume":"135","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"5067","key":"10.1016\/j.jtct.2026.07.001_bib0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.jtct.2026.07.001_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1636978","article-title":"Recent advances in human cytomegalovirus: a comprehensive review of pathogenic mechanisms, virus-host interactions, and antiviral strategies","volume":"16","author":"Xia","year":"2026","journal-title":"Front Immunol"},{"issue":"25","key":"10.1016\/j.jtct.2026.07.001_bib0007","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.001_bib0008","article-title":"Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: a multi-centre observational study","volume":"89","author":"Putzna","year":"2024","journal-title":"J Infect"},{"issue":"21","key":"10.1016\/j.jtct.2026.07.001_bib0009","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/bloodadvances.2021005637","article-title":"Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting","volume":"5","author":"Marzolini","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.07.001_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1639463","article-title":"Increased EBV infection and relapse following haploidentical hematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis: a propensity score matching analysis","volume":"15","author":"Huang","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"issue":"9393","key":"10.1016\/j.jtct.2026.07.001_bib0011","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jtct.2026.07.001_bib0012","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after allogeneic stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jtct.2026.07.001_bib0013","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.001_bib0014","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwait","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jtct.2026.07.001_bib0015","first-page":"4041","article-title":"Functionally active virus-specific T cells that target CMV, EBV, and adenovirus can be rapidly expanded from peripheral blood and prevent viral reactivation after stem cell transplantation","volume":"114","author":"Hanley","year":"2009","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2026.07.001_bib0016","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.jtct.2026.07.001_bib0017","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after HSCT","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000809","article-title":"Pathogen-specific T cells: targeting old enemies and new invaders in transplantation and beyond","volume":"7","author":"Papadopoulou","year":"2023","journal-title":"Hemasphere"},{"issue":"104","key":"10.1016\/j.jtct.2026.07.001_bib0019","doi-asserted-by":"crossref","DOI":"10.3791\/52808","article-title":"Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system","author":"Kumaresan","year":"2015","journal-title":"J Vis Exp"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.001_bib0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.rce.2019.04.002","article-title":"Adoptive immunotherapy with antiviral T cells: methods and results","volume":"220","author":"Arroyo","year":"2020","journal-title":"Rev Clin Esp (Barc)"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.001_bib0021","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000479238","article-title":"Robust production of cytomegalovirus pp65-specific T cells using a fully automated IFN-gamma cytokine capture system","volume":"45","author":"Kim","year":"2017","journal-title":"Transfus Med Hemother"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.001_bib0022","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/CJI.0000000000000197","article-title":"Early experience with CliniMACS prodigy CCS (IFN-gamma) system in selection of virus-specific T cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation","volume":"41","author":"K\u00e1llay","year":"2018","journal-title":"J Immunother"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00198-24","article-title":"Adoptive T-cell therapy for virus-associated diseases","volume":"38","author":"Smith","year":"2025","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf232","article-title":"Virus-specific T-cell therapy for prophylaxis and treatment of cytomegalovirus infections after transplantation: a scoping review","volume":"81","author":"Fung","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.001_bib0027","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium (MAGIC)","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.07.001_bib0028","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","article-title":"A scheme for defining cause of death and its application in the T cell depletion trial","volume":"13","author":"Copelan","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.001_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-27354-6","article-title":"Prophylactic infusion of donor derived CMV specific T cells for the prevention of CMV reactivation following allogeneic HSCT","volume":"15","author":"Barkhordar","year":"2025","journal-title":"Sci Rep"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:42:15Z","timestamp":1786088535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"alternative-id":["S2666636726005348"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and Interim Safety and Efficacy Analysis of a Fast Automated Production of Prophylactic Cytomegalovirus-Specific Cytotoxic T Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}